Effect of cilostazol, a cAMP phosphodiesterase inhibitor, on nitric oxide production by vascular smooth muscle cells

By Ikeda U.   Ikeda M.   Kano S.   Kanbe T.   Shimada K.  

European Journal of Pharmacology, Vol. 314, Iss. 1, 1996-10 ,pp. : 197-202

Elsevier

Access to resources Recommend Favorite

Effect of a cGMP-specific phosphodiesterase inhibitor on retinal function

By Estrade M.   Grondin P.   Cluzel J.   Bonhomme B.   Doly M.  

European Journal of Pharmacology, Vol. 352, Iss. 2, 1998-07 ,pp. : 157-163

Elsevier

Access to resources Recommend Favorite

Zaprinast, a type V phosphodiesterase inhibitor, dilates capacitance vessels in anaesthetised rats

By Ng S.S.W.   Pang C.C.Y.  

European Journal of Pharmacology, Vol. 351, Iss. 3, 1998-06 ,pp. : 323-328

Elsevier

Access to resources Recommend Favorite

Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol

By Sasaki H.   Hashimoto K.   Inada T.   Fukui S.   Iyo M.  

European Journal of Pharmacology, Vol. 282, Iss. 1, 1995-08 ,pp. : 71-76

Elsevier

Access to resources Recommend Favorite

Changes in Choroidal Innervation in Royal College of Surgeons Rats with Hereditary Retinal Degeneration

By  

Cells Tissues Organs, Vol. 162, Iss. 2-3, 1998-12 ,pp. : 112-118

Karger

Access to resources Recommend Favorite